Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early Terlipressin in ACLF-AKI
NCT04416282Completed
- Sponsor
- Institute of Liver and Biliary Sciences
- Start
- Jun 2020
- Primary completion
- Jun 2022
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of terlipressin in hepatorenal syndrome (HRS) and acute kidney injury (AKI) (2 arms), sponsored by Institute of Liver and Biliary Sciences. Primary endpoint: Acute Kidney Injury reversal at Day 7. Started Jun 2020; status: completed.
02
Drugs
terlipressin
03
Conditions
hepatorenal syndrome (HRS)acute kidney injury (AKI)
Beyond the preview
Go deeper on NCT04416282.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04416282.